Previous 10 | Next 10 |
Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma PR Newswire 100% ORR ; 75% CR/sCR; and evidence of durable clinical benefit ...
Arcellx Announces Participation at the BofA Securities 2022 Healthcare Conference PR Newswire FOSTER CITY, Calif. , May 5, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of ...
Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma in an Oral Abstract Session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire -- Company to host a live webc...
Arcellx (ACLX) shares jumped 12% on Monday following a week of declines. Shares of the biotech group opened at $11.23 and hit a high of $11.97 in early afternoon. The stock recently changed hands at $11.94, up 12%, at approximately 1:15 p.m. Based in Maryland, Arcellx has been developing cell...
Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting PR Newswire -- ACLX-002 completely regresses multiple c...
Arcellx press release (NASDAQ:ACLX): FY Cash cash and euivalents $104.6M Net loss of $65M. For further details see: Arcellx reports FY results
Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results PR Newswire -- Completed upsized initial public offering of common stock, raising $142.3 million in gross proceeds including full exercise of underwriters' option to purch...
Arcellx (ACLX) stock hit a 52-week low on Tuesday before modestly moving higher in late morning trading. Shares of the biotech group recently changed hands at $15.09, up 3% at approximately 11:00 a.m. ET. Arcellx shares opened at $14.52, sinking to a 52-week low of $14.18 before moving higher...
Arcellx Announces Participation at the Barclays Global Healthcare Conference PR Newswire FOSTER CITY, Calif. , March 10, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a clinical-stage cell therapy biotechnology company, announced today that chairman and chie...
Arcellx Announces Pre-Clinical Data Presentation for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting 2022 PR Newswire FOSTER CITY, Calif. , ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 14:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 12:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...